Loading...
•
Mar 31, 2021
Ocular Therapeutix Q1 2021 Earnings Report
Ocular Therapeutix reported financial results for the first quarter of 2021 and provided updates on its ophthalmology pipeline.
Key Takeaways
Ocular Therapeutix's first quarter of 2021 saw significant progress, with DEXTENZA® revenue up over 200% year-over-year and a record 16,634 billable units sold. The company is advancing its pipeline, including Phase 2 programs in wet-AMD and glaucoma, and expects to complete a Phase 2 clinical trial in dry eye disease.
DEXTENZA® achieved a quarterly record of 16,634 billable units sold to end customers, representing 15% sequential growth.
DEXTENZA® revenue increased by approximately 220% compared to the first quarter of 2020.
The company presented pre-clinical and clinical data at the 2021 ARVO meeting.
A Phase 2 clinical trial evaluating OTX-DED for dry eye disease has dosed its first patient.
Revenue by Segment
Forward Guidance
The Company believes that existing cash and cash equivalents, as of March 31, 2021, will enable the Company to fund planned operating expenses, debt service obligations and capital expenditure requirements through 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...